
    
      To conduct a randomized controlled trial comparing chemotherapy using UFT/LV and
      immunochemotherapy using UFT/LV combined with PSK in patients with histological stage IIIa
      and IIIb colorectal cancer (adenocarcinoma) who have undergone curative surgery without
      residual cancer (R0) using 3-year disease-free survival rate as primary endpoint, and also to
      analyze the 3-year overall survival, compliance, adverse events, QOL and relationship with
      tumor factors.
    
  